Tacilent
Tacilent is an unverified name with no supporting brand evidence in the supplied sources.
Last updated October 30, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
The supplied evidence does not contain any reference to a brand, company, product, or platform named Tacilent. The only source provided is a press release about Debiopharm's MultiLINK linker technology for antibody-drug conjugates, which mentions no entity called Tacilent. No official website, Wikipedia entry, ownership record, headquarters, founding information, product line, or market activity could be attributed to this name. Because the identity of the subject cannot be established from the evidence, this entry is intentionally minimal and flagged for review. It should not be treated as a validated brand dossier until reliable sources describing a commercial entity named Tacilent are located.
Recent events
Apogee Global RMS launches Rogue Risk Platform powered by Tacilent[2]
Reported:
On October 14, 2026, Apogee Global RMS launched the Rogue Risk Platform, powered by Tacilent, which unifies cyber, physical, and human risk in a single operating apparatus and anchors the firm's Zenith sustained engagement practice.
Apogee Global RMS announces equity investment in Tacilent[2]
Reported:
On October 14, 2026, alongside the launch of the Rogue Risk Platform, Apogee Global RMS announced an equity investment in Tacilent, the platform's developer, with Apogee stating it put capital behind the platform to be accountable for how it performs.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/tacilent · Editorial policy · How profiles are compiled